諾輝健康(06606.HK)初段急彈46.4%創一個月高 胃癌篩查自測產品內地獲批
諾輝健康-B(06606.HK)昨日曾跌見18.86元創上市低後收市僅跌1.6%,今早(7日)大幅高開14.7%報22.1元,初段升幅急擴,曾升最多46.4%高見28.2元創約一個月高,現報25.1元,升30.3%,成交277.5萬股,涉7,004.5萬元。
公司昨收市後公布,收到國家藥監局對將「幽幽管」註冊為三類醫療器械的申請的批准。幽幽管為公司基於糞便樣本檢測幽門螺桿菌的胃癌篩查消費者自測產品,幽門螺桿菌為胃癌發病的主要致癌因子。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.